Prostate Health: BPH, Prostatitis, and Cancer Screening After 40

Three prostate conditions dominate men's urologic care: benign prostatic hyperplasia (BPH), prostatitis, and prostate cancer. They can present with overlapping symptoms — most commonly urinary — but require very different workups and treatments. Understanding the distinction is the first step to sensible screening decisions.

BPH is age-related non-cancerous enlargement of the prostate. It affects roughly 50% of men in their 50s and 80%+ of men in their 80s. Symptoms — collectively called lower urinary tract symptoms (LUTS) — include weak stream, hesitancy, incomplete emptying, frequency, urgency, and nocturia.

First-line treatment is watchful waiting for mild symptoms, alpha-blockers (tamsulosin, alfuzosin) for functional relief, and 5-alpha reductase inhibitors (finasteride, dutasteride) for men with substantially enlarged prostates. Combination therapy is common. Minimally invasive procedures (UroLift, Rezum, water vapor therapy) are appropriate for moderate symptoms that fail medication, with TURP reserved for larger prostates.

Supplements like saw palmetto have shown mixed results in high-quality trials. Beta-sitosterol and pygeum have modest supporting data. None is a substitute for evaluation when symptoms are significant.

Acute bacterial prostatitis presents with fever, chills, perineal pain, and urinary symptoms. It requires prompt antibiotics and sometimes admission. Chronic bacterial prostatitis is less dramatic — recurrent UTIs with the same organism — and needs prolonged antibiotic courses.

Chronic pelvic pain syndrome (CP/CPPS), formerly called chronic non-bacterial prostatitis, is by far the most common form and the most frustrating: pelvic pain, urinary symptoms, and sometimes sexual dysfunction without clear infection. Multimodal treatment — pelvic floor physical therapy, alpha-blockers, anti-inflammatories, stress management, and sometimes low-dose amitriptyline or pregabalin — outperforms single-agent approaches.

Prostate cancer is the most common non-skin cancer in men. Most cases are indolent; some are aggressive. The screening question is not 'should we detect prostate cancer?' but 'how do we detect the cancers that will kill men without over-treating the ones that won't?'

Current consensus (AUA, ACS, USPSTF) recommends a shared decision-making conversation about PSA screening starting at age 50 for average-risk men, age 45 for higher-risk men (Black men, family history), and age 40 for men with strong family history or known BRCA mutations. Screening should generally stop at 70 or when life expectancy is under 10 years.

Elevated PSA does not equal cancer — it can reflect BPH, prostatitis, recent ejaculation, or vigorous cycling. Modern workup adds risk calculators, PSA density, free/total PSA ratio, MRI, and only then targeted biopsy — reducing the historic problem of unnecessary biopsies and overtreatment of indolent disease.

Diet: Mediterranean-style eating patterns rich in tomatoes (lycopene), cruciferous vegetables, and omega-3s are associated with lower aggressive prostate cancer risk in observational data. Very high dairy intake and high red-meat intake show weaker but replicable associations with higher risk.

Exercise: regular aerobic and resistance exercise is associated with lower prostate cancer mortality in survivors and better BPH symptom scores in the general population. Obesity and metabolic syndrome are associated with more aggressive disease.

Selenium and vitamin E: high-dose supplementation showed increased prostate cancer risk in the SELECT trial and should not be used for prevention. Zinc and vitamin D at replacement doses are safe and address common deficiencies.